However, no significant O-glycosylation of DR4 was observed in the present study, suggesting that C2GnT-expressing prostate cancer cells use a different mechanism to control cancer cell-sensitivity to TRAIL from that reported by Wagner et al. The gene discussed is TNFRSF10A; the disease is prostate carcinoma.